ACEI类药物治疗糖尿病肾病的临床疗效观察  

The clinical effect analysis of ACEI for the diabetic nephropathy

作　　者：张梦梦[1] 

机构地区：[1]浙江省杭州市江干区人民医院(笕桥院区)内科,浙江杭州310021

出　　处：《中国当代医药》2012年第1期55-56,共2页China Modern Medicine

摘　　要：目的:探讨ACEI类药物治疗糖尿病肾病的临床疗效。方法:将本院糖尿病专科2009年4月～2010年10月收治的120例患者按照随机数字表随机分成3组,①血管紧张素转换酶抑制剂(ACEI)组,给予贝那普利治疗;②血管紧张素受体拮抗剂(ARB)组,给予缬沙坦治疗;③ACEI+ARB联合用药组,给予缬沙坦与贝那普利。统计分析患者治疗前后24h内的尿蛋白以及血肌酶变化情况,并观察比较各组的耐受性、临床效果与不良反应。结果:ACEI组、ARB组、联合用药组治疗3个月后尿蛋白分别为0.729、1.000、0.825g/L,治疗6个月后分别为0.500、0.375、0.305g/L,A-CEI组、ARB组患者的治疗3、6个月后的尿蛋白及血肌酶变化对比联合用药有一定差异(P<0.05)。结论:ACEI类药物进行联合用药对糖尿病患者的肾功能保护作用会更加明显。Objective： To investigate the clinical efficacy of ACEI drugs in treatment of diabetic nephropathy. Methods： In our hospital diabetes specialist April 2009 to October 2010 120 patients were randomly divided into three groups according to random number table, ① angiotensin-converting enzyme inhibitor （ACEI） group, were given benazepril; ② angiotensin receptor blocker （ARB） group were given valsartan; ③ ACEI and ARB combination treatment group, were given valsartan and benazepril. Statistical analysis before and after treatment within 24 h urine protein and serum muscle enzyme changes, and the tolerance of each group, the clinical effects and adverse reactions were observed. Results： Urinary protein of ACEI group, ARB group, the combined treatment group were 0.729, 1.000, 0.825 g/L after 3 months treatment respectively, and 0.500, 0.375, 0.305 g/L after 6 months of treatment, ACEI group, ARB treatment of patients 3 months, 6 months after the urine protein and serum muscle enzymes in combination with certain changes in contrast differences （P0.05）. Conclusion： ACEI drug combination therapy for patients with diabetes the protective effect of renal function is more obvious.

关 键 词：ACEI类药物 ARB类药物 糖尿病肾病 并发症 

分 类 号：R587.2[医药卫生—内分泌]